BioPhorum’s Technology Roadmap Targets the Technology of Tomorrow

Share Article

Efficiency, modularity, flexibility and innovation will be the hallmarks of the technology in play in the biopharmaceutical industry of tomorrow. These were the main topics of discussion at the Technology Roadmap meeting held at Berkeley, CA on 12-14 April 2016.

The scenarios are a vision of what the manufacturing footprint - and there will be multiple- will look like in the future...

BioPhorum’s Technology Roadmap targets the technology of tomorrow

Efficiency, modularity, flexibility and innovation will be the hallmarks of the technology in play in the biopharmaceutical industry of tomorrow. These were the main topics of discussion at the Technology Roadmap meeting held at Berkeley CA on 12-14 April 2016. According to Steve Jones of Biophorum the objectives of the meeting were “To establish detailed roadmaps for the identified key enabling technologies; build in the perspectives of the new industry stakeholders and ensure that the roadmap fits together and the linkages are clear.”

To reach this point, the Technology Roadmap steering committee of representatives from 18 participating companies created a shared vision of the future by examining the influential market trends, key business drivers and future bio-manufacturing scenarios. Bert Frohlich, Director of Strategy and Technology Lifecycle at Shire, presented a summary of the most important market trends steering the course of the industry which include the introduction of new product classes; continued growth of the biopharmaceutical market; the pressure to reduce costs and uncertainty in approval and sales of new product. According to Frohlich, “The industry as a whole is facing a lot more complexity (and) in the face of rising costs and cost pressures, we can’t get stuck in our old paradigm.”

As a director within Pfizer’s Biomanufacturing Sciences Group, Paul McCormac has a unique understanding of the biopharma manufacturing landscape and played an integral role in identifying the roadmap’s future manufacturing scenarios.

“The scenarios are a vision of what the manufacturing footprint – and there will be multiple – will look like in the future to support the biotech products that are in development…. Essentially what this means is that there won’t be one scenario that fits all the demands – some will be very large scale, disposable with continuous operations, some will be very small scale for these newer, exciting therapies.”

Against this shared vision of the future, six roadmapping teams were mobilised in January and February. With the involvement of suppliers’ R&D Heads and the input from leading academics, the teams are tasked with developing long-term visions for the six technology topics that the committee had identified.

According to Tina Larson, Global Head of Technical Development and Business Operations at Roche, “The roadmapping teams are going to put some more specific technologies and recommendations against the broad-sweep problem statements. Each team has an individual roadmap in terms of where you would invest, so that putting them all together gives a landscape of where the industry will be investing its resources over the next decade.”

The roadmap will act as a guide rail for innovation for the industry, enabling all stakeholders to understand and then contribute to the changing needs of the industry and benefit patients. When complete, The Technology Roadmap will be available free to everyone and updated and published on a regular basis.

The Technology Roadmap is being developed and professionally facilitated by The BioPhorum Operations Group, a highly effective industry collaboration.

For more information go to:- Technology Roadmapping initiative

For interviews please contact: Steve Jones, Director, BioPhorum, Tel: +44 7710 878181    steve(at)biophorum(dot)com     http://www.biophorum.com

Companies taking part in the Technology Roadmap for the biopharmaceutical industry are:
AbbVie, AstraZeneca, Baxalta, Bayer, Biogen, Fujifilm Diosynth Biotechnologies, GSK, ImmunoGen Inc., Janssen, Lonza, Eli Lilly & Co, Merck & Co., Inc. Kenilworth, NJ, USA, Merck KGaA, Darmstadt, Germany, Pfizer, Roche, Sanofi, Shire, Takeda

About The BioPhorum Operations Group

Since its inception in 2004, the BioPhorum has become the open and trusted environment where senior leaders of the biopharma industry come together to openly share and discuss the emerging trends and challenges facing their industry. The strong cross-company relationships built through the Biophorum have provided the solid foundation from which highly effective collaborations have grown, each focusing on the key operational challenges, improving competitiveness and reducing patient risk. As well as The Technology Roadmap, BioPhorum runs 5 other forums – Drug Substance, The Development Group, Fill Finish, IT and Supply Partner.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Ali
BioPhorum
+44 7795386703
Email >

Steve Jones
BioPhorum
+44 7710 878181
Email >
Visit website